Kaihao Xu, Zhaonan Li, Chaoyan Wang, Chuan Tian, Dechao Jiao, Xinwei Han, Yan Yan
{"title":"3.0-T磁共振引导下封闭微波消融术治疗肝穹窿下肝癌:单中心体验","authors":"Kaihao Xu, Zhaonan Li, Chaoyan Wang, Chuan Tian, Dechao Jiao, Xinwei Han, Yan Yan","doi":"10.1080/02656736.2022.2107717","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To analyze the clinical safety and efficacy of 3.0-T closed MR-guided microwave ablation (MWA) for the treatment of HCC located under the hepatic dome.</p><p><strong>Methods: </strong>From May 2018 to October 2020, 49 patients with 74 HCCs located under the hepatic dome underwent MWA using 3.0-T closed MR guidance. The technical success rate, operative time, complete ablation (CA) rate, complications, local tumor progression (LTP), tumor-free survival (TFS) and overall survival (OS) were examined. Routine blood analysis, liver/kidney function and alpha fetoprotein (AFP) and protein induced by vitamin k absent or antagonist (PIVKA) levels were compared before and 2 months after MWA.</p><p><strong>Results: </strong>All patients underwent MWA successfully, including 10 patients who underwent general anesthesia. The technical success rate was 100% without major complications. The CA rate was 95.9% (71/74) at the 2-month evaluation. The LTP rate was 2.7% during the median follow-up of 17.8 months (range: 4-43 months); the 6-, 12-, 18-month TFS rates were 97.8, 90.6, 68.1%, respectively, and the 6-, 12-, 18-month OS rates were 100, 97.6, 92.1%, respectively. There were no significant changes in routine blood tests and liver/kidney function (<i>p</i> > 0.05), while the AFP and PIVKA level decreased significantly at 2 months (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>3.0-T MR-guided MWA is safe and feasible for HCC lesions located under the hepatic dome.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":" ","pages":"1044-1051"},"PeriodicalIF":3.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"3.0-T closed MR-guided microwave ablation for HCC located under the hepatic dome: a single-center experience.\",\"authors\":\"Kaihao Xu, Zhaonan Li, Chaoyan Wang, Chuan Tian, Dechao Jiao, Xinwei Han, Yan Yan\",\"doi\":\"10.1080/02656736.2022.2107717\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To analyze the clinical safety and efficacy of 3.0-T closed MR-guided microwave ablation (MWA) for the treatment of HCC located under the hepatic dome.</p><p><strong>Methods: </strong>From May 2018 to October 2020, 49 patients with 74 HCCs located under the hepatic dome underwent MWA using 3.0-T closed MR guidance. The technical success rate, operative time, complete ablation (CA) rate, complications, local tumor progression (LTP), tumor-free survival (TFS) and overall survival (OS) were examined. Routine blood analysis, liver/kidney function and alpha fetoprotein (AFP) and protein induced by vitamin k absent or antagonist (PIVKA) levels were compared before and 2 months after MWA.</p><p><strong>Results: </strong>All patients underwent MWA successfully, including 10 patients who underwent general anesthesia. The technical success rate was 100% without major complications. The CA rate was 95.9% (71/74) at the 2-month evaluation. The LTP rate was 2.7% during the median follow-up of 17.8 months (range: 4-43 months); the 6-, 12-, 18-month TFS rates were 97.8, 90.6, 68.1%, respectively, and the 6-, 12-, 18-month OS rates were 100, 97.6, 92.1%, respectively. There were no significant changes in routine blood tests and liver/kidney function (<i>p</i> > 0.05), while the AFP and PIVKA level decreased significantly at 2 months (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>3.0-T MR-guided MWA is safe and feasible for HCC lesions located under the hepatic dome.</p>\",\"PeriodicalId\":520653,\"journal\":{\"name\":\"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group\",\"volume\":\" \",\"pages\":\"1044-1051\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/02656736.2022.2107717\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02656736.2022.2107717","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
目的:分析3.0 t磁共振引导下闭式微波消融术(MWA)治疗肝穹下肝细胞癌的临床安全性和有效性。方法:2018年5月至2020年10月，49例74例位于肝穹下的hcc患者采用3.0-T封闭MR引导行MWA。观察技术成功率、手术时间、完全消融(CA)率、并发症、局部肿瘤进展(LTP)、无瘤生存(TFS)和总生存(OS)。比较MWA前后2个月的血常规、肝肾功能、甲胎蛋白(AFP)和维生素k缺失或拮抗剂诱导的蛋白(PIVKA)水平。结果:所有患者均成功行MWA手术，其中10例患者行全身麻醉。技术成功率100%，无重大并发症。2个月时CA率为95.9%(71/74)。在17.8个月(范围:4-43个月)的中位随访期间，LTP率为2.7%;6、12、18个月TFS分别为97.8、90.6、68.1%，6、12、18个月OS分别为100、97.6、92.1%。两组患者血常规、肝肾功能无明显变化(p > 0.05)， 2个月时AFP、PIVKA水平明显下降(p)。结论:3.0 t mr引导下MWA治疗位于肝球下的HCC是安全可行的。
3.0-T closed MR-guided microwave ablation for HCC located under the hepatic dome: a single-center experience.
Purpose: To analyze the clinical safety and efficacy of 3.0-T closed MR-guided microwave ablation (MWA) for the treatment of HCC located under the hepatic dome.
Methods: From May 2018 to October 2020, 49 patients with 74 HCCs located under the hepatic dome underwent MWA using 3.0-T closed MR guidance. The technical success rate, operative time, complete ablation (CA) rate, complications, local tumor progression (LTP), tumor-free survival (TFS) and overall survival (OS) were examined. Routine blood analysis, liver/kidney function and alpha fetoprotein (AFP) and protein induced by vitamin k absent or antagonist (PIVKA) levels were compared before and 2 months after MWA.
Results: All patients underwent MWA successfully, including 10 patients who underwent general anesthesia. The technical success rate was 100% without major complications. The CA rate was 95.9% (71/74) at the 2-month evaluation. The LTP rate was 2.7% during the median follow-up of 17.8 months (range: 4-43 months); the 6-, 12-, 18-month TFS rates were 97.8, 90.6, 68.1%, respectively, and the 6-, 12-, 18-month OS rates were 100, 97.6, 92.1%, respectively. There were no significant changes in routine blood tests and liver/kidney function (p > 0.05), while the AFP and PIVKA level decreased significantly at 2 months (p < 0.05).
Conclusion: 3.0-T MR-guided MWA is safe and feasible for HCC lesions located under the hepatic dome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
